Abnova (Taiwan) (TPE:4133) Notes Receivable: NT$0.0 Mil (As of Dec. 2025)


TPE:4133 Abnova (Taiwan) Corp TPE:4133
75 GF Score
Price NT$21.20
GF Value NT$28.26
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Abnova (Taiwan) Notes Receivable?

Abnova (Taiwan) TPE:4133 +1.68% 75 Notes Receivable is NT$0.0 Mil as of Dec. 2025. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.26 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Abnova (Taiwan)'s Notes Receivable for the quarter that ended in Dec. 2025 was NT$0.0 Mil.

Abnova (Taiwan) Notes Receivable Related Terms

Abnova (Taiwan) Notes Receivable Historical Data

* Premium members only.

The historical data trend for Abnova (Taiwan)'s Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abnova (Taiwan) Notes Receivable Chart

Abnova (Taiwan) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Abnova (Taiwan) Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:4133
75GF Score
Abnova (Taiwan) Corp TPE:4133
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abnova (Taiwan) Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of NT$0.0 Mil mean?
Abnova (Taiwan) (TPE:4133) has a Notes Receivable of NT$0.0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Abnova (Taiwan) and its competitors.
Is Abnova (Taiwan)'s Notes Receivable too high?
Abnova (Taiwan)'s current Notes Receivable is NT$0.0 Mil. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s Notes Receivable compare to VRTX and REGN?
Abnova (Taiwan)'s Notes Receivable of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Abnova (Taiwan) and its competitors. Abnova (Taiwan)'s current Notes Receivable is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.26, compared to a current price of NT$21.20 — trading 25% below its estimated fair value. The current Notes Receivable is NT$0.0 Mil. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current Notes Receivable is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?

Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued. The current stock price of NT$21.20 is trading 25% below its estimated GF Value™ of NT$28.26. GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.

Key valuation signals for TPE:4133:

  • Notes Receivable: NT$0.0 Mil
  • GF Value™: NT$28.26 vs. price of NT$21.20 (25% below fair value)
  • GF Score™: 75/100 with 5 warning signs

No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abnova (Taiwan) Business Description

Address No.108, Jhouzih Street, 9th Floor, Neihu District, Taipei City, TWN
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score

Get the complete analysis for TPE:4133

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.20
Price
NT$28.26
GF Value